Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 2,243 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fasting Clear all
Completed No phase listed Observational Accepts healthy volunteers

Fastomics: Metabolic and Therapeutic Effects of Prolonged Fasting

NCT07216989
View directory record Official record
Conditions
Insulin Resistance, Fasting
Interventions
Fasting
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 17, 2026, 3:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Zonisamide Capsules 100 mg and Zonegran® Capsules 100 mg

NCT00650052
View directory record Official record
Conditions
Healthy
Interventions
Zonisamide Capsules 100 mg, Zonegran® Capsules 100 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 17, 2026, 3:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Conditions

NCT01340625
View directory record Official record
Conditions
Bioequivalence
Interventions
Norethindrone/Ethinyl Estradiol, Ovcon® 35 Fe
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated May 25, 2011 · Synced Oct 17, 2026, 3:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Metabolic Syndrome Feasibility Study

NCT02287766
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Not listed
Lead sponsor
Epic Research & Diagnostics, Inc.
Industry
Eligibility
21 Years to 85 Years
Enrollment
193 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 4, 2015 · Synced Oct 17, 2026, 3:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Motor Imagery Dosage on Motor Learning in Healthy Adults

NCT06299345
View directory record Official record
Conditions
Healthy
Interventions
Motor imagery training, NO motor imagery training
Other
Lead sponsor
Ahmed Mahmoud Kadry
Other
Eligibility
18 Years to 35 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Mequon, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 17, 2026, 3:16 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Prediction of Visual Feedback Effects on Speech Motor Adaptation in Healthy Adults

NCT07530900
View directory record Official record
Conditions
Healthy Volunteers, Speech
Interventions
Altered Auditory Feedback (AAF), Visual-Acoustic Biofeedback
Behavioral
Lead sponsor
New York University
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 17, 2026, 3:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Famciclovir 500 mg Tablets Under Non-Fasting Conditions

NCT00834444
View directory record Official record
Conditions
Healthy
Interventions
Famciclovir 500 mg Tablets, Famvir® 500 mg Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 17, 2026, 3:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Mercaptopurine 50 mg and Purinethol® Tablets 50 mg

NCT00648336
View directory record Official record
Conditions
Healthy
Interventions
Mercaptopurine 50 mg, Purinethol® Tablets 50 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 17, 2026, 3:16 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Training Strategies to Maintain Performance

NCT07128511
View directory record Official record
Conditions
Shortness of Breath, Shortness of Breath/Dyspnea, Respiratory Distress
Interventions
Multiple Inhalation Breathing Pattern, Tactical Breathing Technique
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 17, 2026, 3:16 AM EDT
Completed Not applicable Interventional

Glioma Modified Atkins-based Diet in Patients With Glioblastoma

NCT02286167
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Diet modification
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 17, 2026, 3:16 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)

NCT06562907
View directory record Official record
Conditions
Weight Management
Interventions
GS-4571, Placebo, Omeprazole
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
3
States / cities
Miami, Florida • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 17, 2026, 3:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.

NCT04831944
View directory record Official record
Conditions
Advanced Malignancies
Interventions
parsaclisib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
5
States / cities
Rialto, California • Tustin, California • Hialeah, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 17, 2026, 3:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat

NCT01837719
View directory record Official record
Conditions
Human Immunodeficiency Virus Type 1 (HIV-1)
Interventions
Atazanavir, Cobicistat, Atazanavir/Cobicistat FDC
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 49 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2014 · Synced Oct 17, 2026, 3:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Meloxicam Tablets 15 mg and Mobic® Tablets 15 mg

NCT00649077
View directory record Official record
Conditions
Healthy
Interventions
Meloxicam Tablets 15 mg, Mobic® Tablets 15 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 17, 2026, 3:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Clarithromycin 500mg Tablets Under Fasting Conditions.

NCT00774644
View directory record Official record
Conditions
Healthy
Interventions
Clarithromycin 500mg
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 18, 2008 · Synced Oct 17, 2026, 3:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PT2385-102 Food Effect Study of PT2385 in Healthy Volunteers

NCT02553356
View directory record Official record
Conditions
Healthy
Interventions
PT2385
Drug
Lead sponsor
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Oct 17, 2026, 3:16 AM EDT
Completed Phase 4 Interventional Results available

A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus

NCT02688933
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
HOE901-U300 (Insulin Glargine 300 U/ml), Lantus (Insulin Glargine 100 U/ml), Mandated back ground therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
638 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
99
States / cities
Little Rock, Arkansas • Concord, California • Escondido, California + 80 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 17, 2026, 3:16 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Promotion of Weight Management

NCT04131647
View directory record Official record
Conditions
Overweight
Interventions
Weight Maintenance, Weight Maintenance + Intermittent Fasting
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 75 Years
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 17, 2026, 3:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mg

NCT00650416
View directory record Official record
Conditions
Healthy
Interventions
Carvedilol Tablets 12.5 mg, Coreg® Tablets 12.5 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 17, 2026, 3:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Fasting Conditions

NCT00865436
View directory record Official record
Conditions
Healthy
Interventions
Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, CLUCOVANCE® 5 mg/500 mg Tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 17, 2026, 3:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Strengthening Circadian Signals

NCT03490864
View directory record Official record
Conditions
Improving Cardiometabolic Outcomes in Adults
Interventions
Melatonin 1 mg, Placebos, Meal Timing, NON Meal Timing
Dietary Supplement · Other
Lead sponsor
Northwestern University
Other
Eligibility
35 Years to 54 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 17, 2026, 3:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioavailability Study of Colcrys® Crushed and Sprinkled on Applesauce

NCT01130051
View directory record Official record
Conditions
Healthy
Interventions
Colchicine 0.6 mg tablet
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated May 12, 2011 · Synced Oct 17, 2026, 3:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Non-Fasting Conditions

NCT01182207
View directory record Official record
Conditions
Healthy
Interventions
Drospirenone/Ethinyl Estradiol (Gianvi®), YAZ®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 8, 2010 · Synced Oct 17, 2026, 3:16 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Study of Sulthiame (S-054502) in Participants With Renal Impairment and Matched Healthy Controls

NCT07857837
View directory record Official record
Conditions
Renal Impairment
Interventions
Sulthiame
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Altamonte Springs, Florida • Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 17, 2026, 3:16 AM EDT